Member Posts > Cardiol Therapeutics (NASDAQ: CRDL) Upgraded to 'Strong Buy' - Breakout Potential?
Rodman & Renshaw has upgraded Cardiol Therapeutics (CRDL) to "strong-buy," citing confidence in CardiolRx, its promising Phase II heart disease treatment.
📊 Stock Snapshot:
✅ Price: $1.22 (Feb 15, 2025)
✅ Market Cap: $108M
✅ Debt-Free, Strong Liquidity
📈 Analyst Targets:
🔹 HC Wainwright: Buy, $9.00 Target
🔹 Rodman & Renshaw: Strong Buy, $7.00 Target
🔹 Average Price Target: $8.40
🔥 Institutional investors are increasing their positions-could CRDL be the next big biotech breakout?

#CardiolTherapeutics #CRDL #BiotechStocks #StrongBuy #StockMarket #PharmaInvesting #HealthcareInnovation #CardiolRx #HeartDisease #ClinicalTrials #InvestorAlert #NASDAQ #BiotechInvesting #StockAnalysis #MedicalBreakthroughs